In a return to diabetes R&D, Sanofi has agreed to acquire Provention Bio for US$25 per share in cash, representing a total equity value of approximately US$2.9 B. The transaction is driven by Provention’s Tzield™ (teplizumab-mzwv), a first-in-class therapy approved in the US to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and paediatric patients aged 8 years and older with Stage 2 T1D. Interestingly, Sanofi’s purchase builds on its existing co-promotion agreement with Provention where it is already delivering Tzield to patients in the US.